Leuprolide Acetate

Description : Docosahexaenoic acid (DHA) is a premium, microalgae-derived Omega-3 fatty acid (docosahexaenoic acid) designed for high-end nutritional and pharmaceutical applications like infant nutrition, nutraceutical supplements, and high-performance food ingredients. As a plant-based alternative to fish oil (marine oils), it is 100% vegan and fully certified by EFSA, BRC, FSSAI, Halal & Kosher. Scimplify Life Sciences operates with a world-class manufacturing plant with infrastructure and standards on par with global leaders like DSM and BASF, currently approved by global entities such as Mondelez, GSK, and Reckitt. With a current annual capacity of 100 MT (expanding to 250 MT), we provide DHA in high-stability liquid oils, specialised 10% DHA Beads, and advanced 10% DHA ME & NGLP (Micro-Encapsulated) powders. Our Algal DHA is available as a standard Liquid Oil (40%), an ultra-premium oil (50%), and specialised micro-encapsulated powders (10-17%) designed for maximum stability in dry formulations. As a certified Omega-3 supplier, we are a specialised nutraceutical supplement supplier for Plant-Based Omega-3 High-Strength 17% DHA Powder. Every production lot is supported by complete analytical release dossiers verifying European Pharmacopoeia (Ph. Eur.) and USP monograph compliance, EU Novel Food authorisation, non-GMO status, allergen-free certification, and cGMP compliance. As a globally established Docosahexaenoic Acid supplier with ≥ 40% to ≥ 55% active DHA content, we ensure dependable supply, consistent oxidative stability, and complete regulatory documentation, including Docosahexaenoic Acid CoA and TDS across all liquid oil and microencapsulated powder grades.

Description : Leuprolide acetate (CAS No: 74381-53-6) is a synthetic nonapeptide analogue of naturally occurring gonadotropin-releasing hormone (GnRH/LHRH) featuring a D-leucine substitution at position 6 and an N-ethylamide terminus at position 9, functioning as a high-potency LH-RH receptor agonist that down-regulates pituitary gonadotropin receptors and suppresses downstream steroidogenesis. As the international pharmaceutical sector expands beyond short-acting subcutaneous therapies toward 1-month, 3-month, and 6-month sustained-release biodegradable microspheres and subcutaneous implants, demand across oncology and reproductive endocrinology has intensified. Manufacturing facilities producing advanced parenteral therapeutics face acute quality and yield hurdles, particularly peptide chain truncation during continuous synthesis, aggregation during freeze-drying, and autocatalytic polymer cleavage induced by residual acidic reagents. Global pharmaceutical manufacturers, generic injectables formulators, and contract development organisations resolve these hurdles by sourcing through a certified commercial Leuprolide Acetate API supplier providing an active ingredient assay of ≥ 99.0% on an anhydrous, acetic acid-free basis. Sourcing high-purity leuprolide acetate active pharmaceutical ingredient with controlled trifluoroacetic acid (TFA) counter-ion levels (< 0.10%) protects polylactide-co-glycolide (PLGA) polymer matrices from premature core erosion, eliminates initial drug burst release in depot formulations, and secures long-term room-temperature stability. Every production batch undergoes comprehensive quality control testing and is supplied with batch-specific analytical dossiers confirming European Pharmacopoeia (Ph. Eur.) compliance, EU REACH registration, cGMP adherence, and WHO-GMP certification. We are an established Leuprolide Acetate API supplier with ≥ 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Leuprolide Acetate COA/TDS/SDS. Beyond supply, we support partners with region-specific compliances, GMP quality assurance, and regulatory documentation through global supply chain capabilities and logistics coordination.

Description : We supply high-purity ATS - 8 (Atorvastatin Int.) to drive commercial production and biocatalytic process innovations across the international cardiovascular pharmaceutical, APIs, CDMO bioprocessing, and fine chemical manufacturing sectors. Recognised across global biopharma supply chains as atorvastatin side chain amine, (4R-cis)-6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester, this key chiral synthon contains two stereocentres critical for constructing the enantiomerically pure 3,5-dihydroxyheptanoic acid side chain of atorvastatin calcium. Produced via multi-step enzymatic biotransformation and green biocatalytic aldolase/halohydrin dehalogenase cascades, the chiral intermediate achieves enantiomeric excess values exceeding 99.5% (ee ≥ 99.5%), drastically reducing reliance on heavy-metal resolution catalysts and hazardous organometallic reagents. Global pharmaceutical manufacturers and bioprocess operators are replacing legacy multi-step chemical resolution routes with enzymatic biotransformations, selecting our strictly controlled 99.0% minimum purity grade to prevent diastereomeric contamination and downstream API crystallisation failures. Generic pharmaceutical producers partner with us as their certified global atorvastatin intermediate supplier to protect high-volume statin manufacturing campaigns from raw material impurities and cross-border supply chain bottlenecks. Choosing us as your trusted atorvastatin side chain amine supplier guarantees an advanced bioprocess intermediate that provides excellent batch-to-batch chemical yield, low residual solvent levels, and uniform crystalline powder stability during coupling reactions. Engineering and quality assurance teams can verify our strict material metrics by downloading our batch-specific ATS - 8 COA and TDS documentation, which details precise HPLC purity, chiral optical rotation, residual heavy-metal limits (≤ 10 ppm), and particle size distributions. Accessing our official ATS - 8 TDS ensures compliance with global standards, including European REACH registration, RoHS directives, cGMP compliance, and ISO 9001 quality management rules. Partner with us as your preferred ATS - 8 supplier to lock in commercial intermediate reserves and scale your active pharmaceutical ingredient lines